Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
| Autor: | Eric P. Winer, Julie Najita, Pamela J. DiPiro, Harold J. Burstein, Nan Lin, Ian E. Krop, Erin M. Olson |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
musculoskeletal diseases Oncology congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Antineoplastic Agents Breast Neoplasms Kaplan-Meier Estimate Ado-Trastuzumab Emtansine Antibodies Monoclonal Humanized Lapatinib HER2/neu Young Adult Trastuzumab Internal medicine medicine Humans Maytansine Young adult skin and connective tissue diseases neoplasms Aged Neoplasm Staging Retrospective Studies biology business.industry food and beverages Retrospective cohort study Original Articles Hematology Genes erbB-2 Middle Aged medicine.disease Metastatic breast cancer Surgery Regimen Monoclonal Quinazolines biology.protein Female business medicine.drug |
| Zdroj: | Annals of Oncology. 23:93-97 |
| ISSN: | 0923-7534 |
| Popis: | Background Women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) can respond to multiple lines of anti-HER2 therapy. It is unknown whether these patients will derive further clinical benefit following treatment with trastuzumab-MCC-DM1 (T-DM1). Patients and methods: We retrospectively identified HER2-positive MBC patients treated with T-DM1 and characterized outcomes during subsequent lines of anti-HER2 therapy. Response was determined by a blinded radiology review. Time-dependent analyses were carried out using Kaplan–Meier estimates. Results We identified 23 patients treated with single-agent T-DM1 and report on the 20 patients who discontinued protocol therapy. All patients received trastuzumab-based metastatic therapy before initiation of T-DM1 [median 7 regimens (range 3–14)]. Of these 20 patients, 75% (15 of 20) received further therapy with or without anti-HER2 agents after discontinuing T-DM1. Partial response to either first- or second-subsequent line(s) of therapy was seen in 5 of 15 (33%) treated patients, including 33% (4 of 12) who received a regimen containing trastuzumab and/or lapatinib. Median durations of therapy to first- and second-subsequent regimens after T-DM1 were 5.5 and 6.4 months, respectively. Conclusions In heavily pretreated HER2-positive MBC patients, prior exposure to T-DM1 does not exhaust the potential benefit of ongoing anti-HER2 therapy with trastuzumab- and/or lapatinib-based regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|